3M Company · MMM · FY2025 Q2 · Calendar Q3 2025
3M raises EPS outlook as productivity and innovation support Q2
The current analysis supports a constructive but conditional view: earnings growth, productivity and resilient areas of demand improved the near-term setup, while tariffs, PFAS liabilities and softer end markets remain material constraints. The evidence does not establish that these drivers will persist over the next year.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about MMM FY2025 Q2
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management reported higher adjusted EPS, stronger margin contribution from productivity and cost controls, a PFAS settlement and lower tariff impact. Full-year EPS guidance moved higher, while the company continued emphasizing product launches, commercial excellence and R&D investment.
Guidance delta
Management raised full-year EPS guidance to $7.75-$8 from $7.60-$7.90 previously.
Key takeaways
- Management reported adjusted EPS of $2.16, up 12% year over year, with organic sales growth of 1.5%.
- Productivity and cost controls added 290 basis points to operating margin, while free cash flow was $1.3 billion.
- The company launched 64 new products in Q2 and highlighted reduced tariff impact and a PFAS settlement.
- The next test is whether innovation and commercial-excellence initiatives can offset demand, tariff and litigation risks.
Management priorities
- Maintain the new-product launch cadence.
- Continue commercial-excellence initiatives across business groups.
- Exit PFAS manufacturing by year-end and manage related legal matters.
- Invest in R&D and sales capacity while pursuing productivity gains.
- Return $3 billion to shareholders through dividends and buybacks while preserving balance-sheet flexibility.
Follow MMM with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wolfe Research | Peer Perform | Outperform | Downgrade | Nov 12, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 5, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2026 |
| RBC Capital | Underperform | Underperform | Maintain | Oct 21, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Oct 21, 2026 |
| Bernstein | Market Perform | Market Perform | Maintain | Oct 21, 2026 |
| Mizuho | Neutral | Neutral | Maintain | Jul 23, 2026 |
| UBS | Buy | Buy | Maintain | Jul 22, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 22, 2026 |
| Barclays | Overweight | Overweight | Maintain | Apr 1, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jan 21, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Jan 21, 2026 |
| B of A Securities | Buy | Buy | Maintain | Mar 6, 2025 |
| Melius Research | Buy | Hold | Upgrade | Oct 22, 2024 |
| Argus Research | Buy | Hold | Upgrade | Jul 30, 2024 |
| Vertical Research | Buy | Hold | Upgrade | May 16, 2024 |
| HSBC | Buy | Hold | Upgrade | May 10, 2024 |
| DA Davidson | Buy | Buy | Maintain | Jul 11, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Mar 29, 2023 |
| Jefferies | Hold | Hold | Maintain | Jun 16, 2022 |
| CFRA | Hold | Sell | Upgrade | Mar 8, 2022 |
| Langenberg & Company | Buy | Hold | Upgrade | Oct 10, 2021 |
| Gordon Haskett | Hold | Underperform | Upgrade | Oct 7, 2020 |
| Bank of America | Neutral | Neutral | Maintain | Jun 27, 2019 |
| Argus | Hold | Buy | Downgrade | Apr 26, 2019 |
| Stifel Nicolaus | Hold | Hold | Maintain | Apr 25, 2018 |
| Stifel | Hold | Hold | Maintain | Apr 25, 2018 |
| Hilliard Lyons | Buy | Neutral | Upgrade | Jan 24, 2018 |
| Argus Capital | Buy | Hold | Upgrade | Jul 8, 2014 |
| William Blair | Market Perform | Market Perform | Maintain | Feb 25, 2014 |
| Ladenburg Thalmann | Hold | Hold | Maintain | Dec 26, 2013 |
| Nomura | Buy | Neutral | Upgrade | Dec 11, 2013 |
| FBR Capital | Outperform | Outperform | Maintain | Oct 25, 2013 |
Named analyst price targets
Upside is calculated against the persisted current price $177.99. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Amit Mehrotra | $230 | $192.63 | +29.2% | Nov 4, 2026 |
| Bernstein | Varun Govindaraj | $197 | $170.9 | +10.7% | Oct 21, 2026 |
| RBC Capital | Jeffrey Reive | $135 | $170.14 | -24.2% | Oct 21, 2026 |
| J.P. Morgan | Chigusa Katoku | $191 | $174.74 | +7.3% | Oct 21, 2026 |
| Citigroup | Analyst unavailable | $188 | $174.74 | +5.6% | Oct 21, 2026 |
| Jefferies | Laurence Alexander | $186 | $171.37 | +4.5% | Oct 21, 2026 |
| Bernstein | Analyst unavailable | $171 | $167.52 | -3.9% | Sep 25, 2026 |
| Wells Fargo | Analyst unavailable | $195 | $167.52 | +9.6% | Sep 24, 2026 |
| Mizuho Securities | Analyst unavailable | $180 | $170.08 | +1.1% | Jul 23, 2026 |
| Deutsche Bank | Nicole Deblase | $192 | $173.97 | +7.9% | Jul 22, 2026 |
| UBS | Analyst unavailable | $218 | $170.76 | +22.5% | Jul 22, 2026 |
| Bernstein | Varun Govindaraj | $145 | $170.76 | -18.5% | Jul 22, 2026 |
| Goldman Sachs | Analyst unavailable | $190 | $158.32 | +6.7% | Jun 15, 2026 |
| Deutsche Bank | Analyst unavailable | $181 | $158.06 | +1.7% | Jan 21, 2026 |
| Mizuho Securities | Brett Linzey | $160 | $157.45 | -10.1% | Jan 21, 2026 |
| RBC Capital | Deane Dray | $136 | $156.09 | -23.6% | Jan 21, 2026 |
| RBC Capital | Deane Dray | $131 | $172.79 | -26.4% | Jan 15, 2026 |
| Deutsche Bank | Nicole Deblase | $178 | $167.48 | +0.0% | Dec 8, 2025 |
| Barclays | Analyst unavailable | $190 | $173.09 | +6.7% | Dec 4, 2025 |
| UBS | Amit Mehrotra | $190 | $166.64 | +6.7% | Oct 22, 2025 |
| Barclays | Julian Mitchell | $180 | $166.64 | +1.1% | Oct 22, 2025 |
| Morgan Stanley | Analyst unavailable | $160 | $166.64 | -10.1% | Oct 21, 2025 |
| Barclays | Julian Mitchell | $170 | $159.04 | -4.5% | Jul 18, 2025 |
| UBS | Markus Mittermaier | $184 | $130.35 | +3.4% | Nov 12, 2024 |
| Bank of America Securities | Andrew Obin | $160 | $129.04 | -10.1% | Oct 23, 2024 |
| RBC Capital | Deane Dray | $100 | $131.73 | -43.8% | Oct 23, 2024 |
| CFRA | Jonathan Sakraida | $165 | $131.73 | -7.3% | Oct 22, 2024 |
| Citigroup | Andrew Kaplowitz | $133 | $134.84 | -25.3% | Oct 22, 2024 |
| Mizuho Securities | Brett Linzey | $146 | $135.73 | -18.0% | Oct 16, 2024 |
| Barclays | Julian Mitchell | $160 | $137.06 | -10.1% | Oct 2, 2024 |
| Jefferies | Laurence Alexander | $146 | $135.64 | -18.0% | Sep 24, 2024 |
| Morgan Stanley | Christopher Snyder | $125 | $131.4 | -29.8% | Sep 6, 2024 |
| Deutsche Bank | Nicole Deblase | $150 | $126.94 | -15.7% | Jul 31, 2024 |
| Argus Research | John Eade | $145 | $126.75 | -18.5% | Jul 30, 2024 |
| RBC Capital | Deane Dray | $95 | $125.3 | -46.6% | Jul 29, 2024 |
| Barclays | Julian Mitchell | $120 | $103.39 | -32.6% | Jul 26, 2024 |
| RBC Capital | Deane Dray | $78 | $94.02 | -56.2% | Apr 2, 2024 |
| CFRA | Jonathan Sakraida | $100 | $94.02 | -43.8% | Apr 1, 2024 |
| RBC Capital | Deane Dray | $84 | $108.11 | -52.8% | Mar 20, 2024 |
| Barclays | Julian Mitchell | $126 | $105.32 | -29.2% | Mar 19, 2024 |
| Citigroup | Andrew Kaplowitz | $104 | $92.42 | -41.6% | Feb 15, 2024 |
| Morgan Stanley | Joshua Pokrzywinski | $113 | $93 | -36.5% | Sep 28, 2023 |
| J.P. Morgan | Stephen Tusa | $105 | $97.03 | -41.0% | May 25, 2023 |
| Morgan Stanley | Joshua Pokrzywinski | $102 | $100.96 | -42.7% | May 10, 2023 |
| Mizuho Securities | Brett Linzey | $130 | $120.66 | -27.0% | Dec 27, 2022 |
| Wells Fargo | Joseph O’Dea | $137 | $128.31 | -23.0% | Jul 15, 2022 |
| Deutsche Bank | Nicole DeBlase | $146 | $128.37 | -18.0% | Jul 14, 2022 |
| Barclays | Julian Mitchell | $143 | $126.59 | -19.7% | Jul 14, 2022 |
| Jefferies | Laurence Alexander | $145 | $129.84 | -18.5% | Jun 20, 2022 |
| Barclays | Analyst unavailable | $146 | $145.41 | -18.0% | Apr 27, 2022 |
| Credit Suisse | Analyst unavailable | $161 | $144.88 | -9.5% | Apr 27, 2022 |
| Morgan Stanley | Analyst unavailable | $138 | $144.87 | -22.5% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $138 | $144.22 | -22.5% | Apr 27, 2022 |
| Deutsche Bank | Nicole DeBlase | $167 | $146.18 | -6.2% | Apr 19, 2022 |
| Barclays | Julian Mitchell | $155 | $148.9 | -12.9% | Apr 5, 2022 |
| Wells Fargo | Joseph O’Dea | $173 | $147.62 | -2.8% | Feb 21, 2022 |
| Deutsche Bank | Nicole Deblase | $182 | $155.83 | +2.3% | Feb 15, 2022 |
| Argus Research | John Eade | $190 | $167.68 | +6.7% | Jan 26, 2022 |
| Credit Suisse | John Walsh | $195 | $169.3 | +9.6% | Jan 26, 2022 |
| Wolfe Research | Nigel Coe | $190 | $167.68 | +6.7% | Jan 26, 2022 |
| Bernstein | Brendan Luecke | $175 | $175.71 | -1.7% | Jan 10, 2022 |
| Bank of America Securities | Andrew Obin | $185 | $178.3 | +3.9% | Sep 17, 2021 |
Track every rating change on MMM the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publication3M Company operates as a global technology conglomerate with diverse interests. Its extensive operations are strategically divided into four primary business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial division supplies a broad array of products, including specialized abrasives and finishing tools for metalworking, automotive body repair kits, fastening systems for personal hygiene items, various masking and packaging materials, electrical components for construction, maintenance, and power distribution, strong structural adhesives and tapes, comprehensive personal protective equipment for respiratory, auditory, visual, and fall protection, and mineral granules for roofing shingles.…
Historical context
All MMM earningsIndustrials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| FRO Frontline Plc | FY2026 Q3 · Calendar Q4 2026 | -11.5% | +1.0% | Frontline posts record Q3 profit as spot tanker rates surge |
| WWD Woodward, Inc. | FY2026 Q4 · Calendar Q4 2026 | +11.4% | +6.9% | Woodward reports record FY2026 results and outlines growth priorities for 2027 |
| ZTO ZTO Express (Cayman) Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.9% | -0.7% | Volume and retail-parcel growth support profit gains, with guidance cautious |
| ESLT Elbit Systems Ltd. | FY2026 Q3 · Calendar Q4 2026 | +1.4% | +5.8% | Elbit’s record backlog supports raised 2027 growth outlook, with execution risks |
| ACM Aecom | FY2026 Q4 · Calendar Q4 2026 | — | +11.1% | AECOM closes FY2026 with record backlog and margin; FY2027 outlook maintained |
| ARMK Aramark | FY2026 Q4 · Calendar Q4 2026 | -6.0% | +2.7% | Aramark Posts Record FY2026, Targets 9–10% Organic Growth in FY2027 |
Latest beats and misses
Who reports nextBeat on EPS
- BJFY2026 Q3 · November 20, 2026+37.3% EPS-5.4% move
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
Missed on EPS
- FROFY2026 Q3 · November 20, 2026-11.5% EPS+1.0% move
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
Get the MMM recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-07T03:50:43.019604+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-07T03:50:43.016819+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-07. For educational purposes only; not investment advice.